You are here

UCF Digital Collections ยป ETD Collection

THE IMPACT OF PRE-OPERATIVE MUPIROCIN PROPHYLAXIS ON SURGICAL SITE INFECTIONS IN SAME-DAY ADMISSION OPEN HEART PATIENTS

Download pdf | Full Screen View

Date Issued:
2010
Abstract/Description:
ABSTRACT The CDC estimates that one in 20 patients admitted to the hospital is a carrier of methicillin-resistant Staphylococcus aureus (MRSA). Staphylococci are commonly found on the skin and mucous membranes within the anterior nares, which provides the principle reservoir for this organism. These organisms can go on to cause surgical site infections in hospitalized patients. Mupirocin is an effective topical medication used to eliminate nasal carriage of Staphylococcus aureus (S. aureus). Based on Level A evidence, the 2007 Society of Thoracic Surgeons has made a Class I recommendation for the use of mupirocin for all patients undergoing cardiac surgery in the absence of documentation of a negative culture for staphylococcal colonization. The purpose of this before-and-after study is to examine the rates of surgical site infections (SSI) for cardiac surgery patients who came through the pre-admission testing unit prior to same-day admission (SDA) for surgery before and after providing 2% mupirocin nasal ointment. Specific aims: 1. To examine the relationship between providing mupirocin to the SDA cardiac surgery patient and the prevalence of SSI. 2. To examine the cost-effectiveness of providing mupirocin to the SDA cardiac surgery patient and SSI. 3. To examine the adherence of SDA preoperative cardiac surgery patients and the use of mupirocin preoperatively, if the medication is provided at no cost to the patient. Retrospective chart reviews were completed on 330 patients: 175 patients in the pre-provision of mupirocin and 150 in the mupirocin provided group. Chi Square and studentsÂÂÂÂ' t-tests were used to analyze the data. There were five SSIs in the pre-provision of mupirocin group and no SSIs in the mupirocin provided group. This was a significantly statistical difference between the groups (X2 = 4.497, p < 0.5) Continued provision of 2% nasal mupirocin to prevent SSI in the cardiac surgery patients is recommended.
Title: THE IMPACT OF PRE-OPERATIVE MUPIROCIN PROPHYLAXIS ON SURGICAL SITE INFECTIONS IN SAME-DAY ADMISSION OPEN HEART PATIENTS.
32 views
12 downloads
Name(s): Gerry, Joanna, Author
Wink, Diane, Committee Chair
University of Central Florida, Degree Grantor
Type of Resource: text
Date Issued: 2010
Publisher: University of Central Florida
Language(s): English
Abstract/Description: ABSTRACT The CDC estimates that one in 20 patients admitted to the hospital is a carrier of methicillin-resistant Staphylococcus aureus (MRSA). Staphylococci are commonly found on the skin and mucous membranes within the anterior nares, which provides the principle reservoir for this organism. These organisms can go on to cause surgical site infections in hospitalized patients. Mupirocin is an effective topical medication used to eliminate nasal carriage of Staphylococcus aureus (S. aureus). Based on Level A evidence, the 2007 Society of Thoracic Surgeons has made a Class I recommendation for the use of mupirocin for all patients undergoing cardiac surgery in the absence of documentation of a negative culture for staphylococcal colonization. The purpose of this before-and-after study is to examine the rates of surgical site infections (SSI) for cardiac surgery patients who came through the pre-admission testing unit prior to same-day admission (SDA) for surgery before and after providing 2% mupirocin nasal ointment. Specific aims: 1. To examine the relationship between providing mupirocin to the SDA cardiac surgery patient and the prevalence of SSI. 2. To examine the cost-effectiveness of providing mupirocin to the SDA cardiac surgery patient and SSI. 3. To examine the adherence of SDA preoperative cardiac surgery patients and the use of mupirocin preoperatively, if the medication is provided at no cost to the patient. Retrospective chart reviews were completed on 330 patients: 175 patients in the pre-provision of mupirocin and 150 in the mupirocin provided group. Chi Square and studentsÂÂÂÂ' t-tests were used to analyze the data. There were five SSIs in the pre-provision of mupirocin group and no SSIs in the mupirocin provided group. This was a significantly statistical difference between the groups (X2 = 4.497, p < 0.5) Continued provision of 2% nasal mupirocin to prevent SSI in the cardiac surgery patients is recommended.
Identifier: CFE0003342 (IID), ucf:48461 (fedora)
Note(s): 2010-08-01
D.N.P.
Health and Public Affairs, School of Nursing
Masters
This record was generated from author submitted information.
Subject(s): cardiac surgery
mupirocin prophylaxis
MRSA
Persistent Link to This Record: http://purl.flvc.org/ucf/fd/CFE0003342
Restrictions on Access: public
Host Institution: UCF

In Collections